Stock comparison
Genmab A/S
IRadimed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
IRMD
IRadimed
Market cap
$1.18B
Sector
Healthcare
Overall winner
IRadimed IRMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | IRMD | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 68B | IRMD |
| Benjamin Graham | 64C | 89A | IRMD |
| Philip Fisher | 48D | 92A | IRMD |
| Peter Lynch | 25F | 76B | IRMD |
| Joel Greenblatt | 76B | 65C | GMAB |
| Charlie Munger | 68C | 78B | IRMD |
| Terry Smith | 71C | 75B | IRMD |
Side-by-side metrics
| Metric | GMAB | IRMD |
|---|---|---|
| Market cap | $16.5B | $1.18B |
| P/E (TTM) | 6.2x | 50.4x |
| EV/EBIT | 12.0x | 43.4x |
| ROIC (TTM) | 43.78% | 21.38% |
| Gross margin | 93.88% | 76.84% |
| Net margin | 18.23% | 27.36% |
| Revenue CAGR 5y | -18.45% | 18.99% |
| EPS CAGR 5y | -23.48% | 23.53% |
| Debt / Equity | 0.1x | - |
| Dividend yield | 0.0% | 1.33% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Market cap$16.5Bvs $1.18B+93%
- P/E (TTM)6.2xvs 50.4x+88%
- EV/EBIT12.0xvs 43.4x+72%
- ROIC (TTM)43.78%vs 21.38%+51%
IRMD leads on
- EPS CAGR 5y23.53%vs -23.48%+200%
- Revenue CAGR 5y18.99%vs -18.45%+197%
- Debt / Equity-vs 0.1x+100%
- Dividend yield1.33%vs 0.0%+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.